Cited 2 times in
Cost-utility analysis of pralatrexate for relapsed or refractory peripheral T-cell lymphoma based on a case-matched historical control study along with single arm clinical trial
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2022-09-01T01:18:45Z | - |
dc.date.available | 2022-09-01T01:18:45Z | - |
dc.date.issued | 2020-11 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/189904 | - |
dc.description.abstract | BackgroundPatients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) treated with pralatrexate have previously shown superior overall survival (OS) compared to those who underwent conventional chemotherapy (CC, 15.4 vs. 4.07months). We conducted an economic evaluation of pralatrexate from a societal perspective in Korea based on data from the PROPEL phase II study.MethodsUsing a Markov model with a weekly cycle, we simulated the experience of patients with R/R PTCL receiving pralatrexate or CC for 15years. The model consists of five health states; initial treatment, treatment pause, subsequent treatment, stem cell transplantation (SCT) success, and death. Comparative effectiveness was based on PROPEL phase II single-arm study and its matched historical control analysis. Costs included drug, drug administration, monitoring, adverse event management, and SCT costs.ResultsThe incremental cost-effectiveness ratio of the base case was $39,153 per quality-adjusted life-year (QALY) gained. The results of one-way sensitivity analysis ranged from $33,949 to $51,846 per QALY gained, which remained within an implicit willingness-to-pay (WTP) threshold of anticancer drugs in Korea.ConclusionsPralatrexate is a cost-effective intervention with improved OS and incremental costs within the WTP limit. Pralatrexate could function as a new therapeutic option for patients suffering from life-threatening R/R PTCL. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | BioMed Central | - |
dc.relation.isPartOf | BMC CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Aminopterin / analogs & derivatives* | - |
dc.subject.MESH | Aminopterin / economics | - |
dc.subject.MESH | Aminopterin / pharmacology | - |
dc.subject.MESH | Aminopterin / therapeutic use | - |
dc.subject.MESH | Case-Control Studies | - |
dc.subject.MESH | Cost-Benefit Analysis | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lymphoma, T-Cell, Peripheral / drug therapy* | - |
dc.subject.MESH | Lymphoma, T-Cell, Peripheral / economics* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Neoplasm Recurrence, Local | - |
dc.title | Cost-utility analysis of pralatrexate for relapsed or refractory peripheral T-cell lymphoma based on a case-matched historical control study along with single arm clinical trial | - |
dc.type | Article | - |
dc.contributor.college | Graduate School of Public Health (보건대학원) | - |
dc.contributor.department | Graduate School of Public Health (보건대학원) | - |
dc.contributor.googleauthor | Seonyoung Park | - |
dc.contributor.googleauthor | Ah-Young Kim | - |
dc.contributor.googleauthor | Hyeonseok Cho | - |
dc.contributor.googleauthor | Deborah Baik | - |
dc.contributor.googleauthor | Hankil Lee | - |
dc.contributor.googleauthor | Sunghwa Cho | - |
dc.contributor.googleauthor | Hye-Young Kang | - |
dc.identifier.doi | 10.1186/s12885-020-07629-z | - |
dc.relation.journalcode | J00351 | - |
dc.identifier.eissn | 1471-2407 | - |
dc.identifier.pmid | 33243162 | - |
dc.subject.keyword | Case-matched control analysis | - |
dc.subject.keyword | Cost-utility analysis | - |
dc.subject.keyword | Peripheral T-cell lymphoma | - |
dc.subject.keyword | Pralatrexate | - |
dc.citation.volume | 20 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 1157 | - |
dc.identifier.bibliographicCitation | BMC CANCER, Vol.20(1) : 1157, 2020-11 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.